Suven Life Sciences secures Product Patents in New Zealand and Sri Lanka

Deepthi | Myequity news | Date : 14-09-2018 12:40:00 IST

Suven Life Sciences Ltd (Suven) announces today that the grant of one product patent from New Zealand (728918) and one product patent from Sri Lanka (17300) corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034 and 2031 respectively.

The granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.


About Suven Life Sciences:

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase I completed SUVN-D4010, Phase I commenced SUVN-911 and Phase I ready SUVN-I6107. In addition to these clinical compounds the Company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.


More from Myequity